Cellectis announced that the FDA has granted Orphan Drug Designation, or ODD, to Cellectis’ CLLS52, an Investigational Medicinal Product used as part of the lymphodepletion regimen associated with UCART22, evaluated in the BALLI-01 clinical trial in relapsed/refractory B-cell acute lymphoblastic leukemia.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS:
- Cellectis Gains FDA Orphan Drug Status for ALL Therapy
- FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
- CLLS Earnings this Week: How Will it Perform?
- Cellectis Gains FDA Designations for Leukemia Therapy
- FDA grants Cellectis’ UCART22 ODD and RPDD status for ALL treatment